In the mouse KEP1-11 breast cancer model, the combination treatment of TRC105 and VEGF targeting resulted in decreased tumor vessel density, surprisingly without significantly affecting primary tumor growth [35]. This evidence concerns the gene VEGFA and neoplasm.